We've partnered with Elpida Therapeutics to advance 3 clinical gene therapy programmes for ultra-rare childhood neurodegenerative diseases: Spastic Paraplegia type 50 (SPG50), CLN7 Batten disease and Charcot–Marie–Tooth type 4J. The first children are already taking part in a Phase III SPG50 trial.
